BioSpace News Archive

Drug Development

Lilly’s Retevmo® (selpercatinib) Phase 3 Results in RET Fusion-Positive NSCLC and RET-Mutant Medullary Thyroid Cancer Both Published in The New England Journal of Medicine and Presented in a Presidential Symposium at ESMO Congress 2023

Eli Lilly and Company announced results from both the LIBRETTO-431 Phase 3 study, which evaluated Retevmo® versus platinum-based chemotherapy.

October 21, 2023
·
23 min read
Business

Foundation Medicine Expands Partnership with Sequanta to Provide both Liquid and Tissue Genomic Profiling Services in China to Support Global Regulatory Filings

Foundation Medicine, Inc., announced that it has expanded its partnership with Sequanta Technologies Co., Ltd. to provide genomic profiling services to support clinical research and the development of oncology therapies in China.

October 21, 2023
·
6 min read
Pharm Country

AnHeart Therapeutics’ Investigational Medicine Taletrectinib Shrank Tumors in More Than 90 Percent of People With ROS1-Positive Non-Small Cell Lung Cancer Who Were ROS1 TKI Naïve in Global Pivotal TRUST-II Trial

AnHeart Therapeutics, a global clinical-stage biopharmaceutical company developing novel precision therapies for people with cancer, announced positive interim results from its global pivotal Phase 2 clinical trial, TRUST-II.

October 21, 2023
·
7 min read
Drug Development

TAGRISSO® (osimertinib) plus chemotherapy reduced the risk of disease progression in the brain by 42% in patients with EGFR-mutated advanced lung cancer and brain metastases at baseline

Results from a prespecified exploratory analysis of the FLAURA2 Phase III trial showed AstraZeneca.

October 21, 2023
·
12 min read
Drug Development

Initial Phase 1 Dose Escalation Data of ORIC-114 in Patients with EGFR and HER2 Exon 20 Mutations Demonstrates Potential Best-In-Class Profile

ORIC Pharmaceuticals, Inc. announced initial data from the ongoing ORIC-114 Phase 1 dose escalation trial for patients with EGFR or HER2 exon 20 mutated non-small cell lung cancer at the European Society of Medical Oncology Congress 2023.

October 21, 2023
·
10 min read
Genetown

Precede Biosciences Unveils Groundbreaking Clinical Data for its Pioneering Liquid Biopsy Platform at ESMO 2023 and Simultaneously Publishes in Nature Medicine

Precede Biosciences announced the first clinical data from its proprietary liquid biopsy platform were presented in an oral presentation at the European Society for Medical Oncology Congress in Madrid, Spain, and simultaneously published in Nature Medicine.

October 21, 2023
·
4 min read